A Study of Intermittent Oral Dosing of ASP1517 in ESA-untreated Chronic Kidney Disease Patients With Anemia
A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 100 participants.
Also called NCT02964936
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; no masking; primary purpose treatment
- Phase
- Phase 3
- Enrolled
- 100 participants
- Sponsor
- Registry
-
NCT02964936
-
- Started
- (actual)
- Primary completion
- (actual)
- Completion
- (actual)
- Countries
- Japan
- Registry status
- Completed
Technical summary
Registry record NCT02964936. Randomized; no masking; primary purpose treatment. Start 2017-01-11 (actual); primary completion 2018-08-15 (actual). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- A Study of Intermittent Oral Dosing of ASP1517 in ESA-untreated Chronic Kidney Disease Patients With Anemia
- Condition
- Chronic Kidney Disease
- Intervention (Drug)
- roxadustat
- Lead sponsor
- Astellas Pharma Inc
- Collaborator
- Kyntra Bio
Record details
- Record id
cardio:ct-nct02964936- Content hash
5500c4349dc2f99a9d13516182360b1ec0660a2e520e16470d779d130d0b6735